Septerna to Participate in Two Upcoming Investor Conferences in September
News provided bySepterna, Inc · 1 min read
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 /CourierPR/ -- Septerna, a clinical-stage biotechnology company focused on pioneering new G protein-coupled receptor (GPCR) drug discovery, will participate in two upcoming investor conferences in September.
On Tuesday, September 8, 2026, at 8:00 a.m. ET, Septerna’s management will host a fireside chat at the Wells Fargo 21st Annual Healthcare Conference. The conversation will be live-streamed and archived on the company’s website, available in the investors section at www.septerna.com for at least 30 days following the event.
On Thursday, September 10, 2026, at 11:30 a.m. ET, the company will also present at the Cantor Global Healthcare Conference 2026, providing further insights into its proprietary Native Complex Platform® and the progress of its drug discovery programs.
Septerna, Inc., founded with a team of GPCR experts and dedicated drug developers, is advancing cutting-edge science to address significant unmet needs in patients. The company’s proprietary platform is designed to facilitate new approaches in GPCR drug discovery, leading to the development of diverse oral small molecule drug candidates. Septerna’s pipeline includes programs in endocrinology, immunology and inflammation, metabolic diseases, and additional therapeutic areas, both independently and in partnership with others.